Profil
Hartmut J.
Ehrlich is currently the Chief Executive Officer at Wittycell SAS and Director at Spikimm SAS.
Previously, he was the Chief Executive Officer at Abivax SA from 2013 to 2023 and Head-Global Research & Development at Baxter International, Inc. from 2006 to 2013.
Postes actifs de Hartmut Ehrlich
| Sociétés | Poste | Début |
|---|---|---|
Wittycell SAS
 Wittycell SAS Pharmaceuticals: MajorHealth Technology Wittycell SAS engages in the research and development, manufacturing, and sale of therapeutic and prophylactic vaccines. It offers novel adjuvant products against infectious diseases and cancer. The company was founded in August 2005 and is headquartered in Reims, France. | Chief Executive Officer | - |
| Spikimm SAS | Director/Board Member | - |
Anciens postes connus de Hartmut Ehrlich
| Sociétés | Poste | Fin |
|---|---|---|
| ABIVAX | Chief Executive Officer | 05/05/2023 |
| BAXTER INTERNATIONAL INC. | Chief Tech/Sci/R&D Officer | 01/09/2013 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BAXTER INTERNATIONAL INC. | Health Technology |
| ABIVAX | Health Technology |
| Entreprise privées | 2 |
|---|---|
Wittycell SAS
Wittycell SAS Pharmaceuticals: MajorHealth Technology Wittycell SAS engages in the research and development, manufacturing, and sale of therapeutic and prophylactic vaccines. It offers novel adjuvant products against infectious diseases and cancer. The company was founded in August 2005 and is headquartered in Reims, France. | Health Technology |
| Spikimm SAS |
